Transgenomic Announces Issuance of New European Patent Covering COLD-PCR Technologies
July 31 2014 - 7:00AM
Business Wire
Expansion of Intellectual Property in
European Union Strengthens Coverage of Breakthrough DNA
Amplification Technology Enabling Highly Sensitive “Liquid
Biopsies”
Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology
company advancing personalized medicine in cardiology, oncology,
and inherited diseases through advanced diagnostic tests and
clinical and research services, today announced that the European
Patent Office has issued a new patent, European Patent No.
21833798, covering one of its COLD-PCR family of DNA amplification
technologies. The patent covers Full COLD-PCR, a foundation for the
company’s highly sensitive ICE COLD-PCR technology. The COLD-PCR
technology is owned by the Dana-Farber Cancer Institute, Boston
USA, and exclusively licensed to Transgenomic.
Paul Kinnon, President and Chief Executive Officer of
Transgenomic, commented, “This newly-issued patent provides broad
intellectual property protection for a foundation of our ICE
COLD-PCR technology, which enables researchers and clinicians to
detect and monitor the genomic status of tumors by analyzing
circulating tumor-derived DNA present in minute quantities in the
blood or urine of patients. This approach has already demonstrated
the potential to transform cancer research and treatment. It is
expected to significantly improve patient care by enabling ongoing
monitoring of response to therapy while reducing the need for
invasive tissue biopsies.”
The new European patent helps extend the scope and longevity of
the COLD-PCR intellectual property portfolio, which was originally
developed by the laboratory of Dr. Mike Makrigiorgos at the
Dana-Farber Cancer Institute. Transgenomic is also pursuing
additional European patent coverage specific to ICE COLD-PCR
technology.
ICE COLD-PCR can detect mutated tumor-derived DNA with high
sensitivity in patient specimens that contain large amounts of
“normal” DNA, such as blood, urine or tissue, thereby enabling DNA
analysis of the tumor without the need for tissue biopsy.
About TransgenomicTransgenomic, Inc. is a global
biotechnology company advancing personalized medicine in
cardiology, oncology, and inherited diseases through advanced
diagnostic technologies, such as its revolutionary ICE COLD-PCRTM
and its unique genetic tests provided through its Patient Testing
business. The company also provides specialized clinical and
research services to biopharmaceutical companies developing
targeted therapies and sells equipment, reagents and other
consumables for applications in molecular testing and cytogenetics.
Transgenomic’s diagnostic technologies are designed to improve
medical diagnoses and patient outcomes.
Forward-Looking StatementsCertain statements in this
press release constitute “forward-looking statements” of
Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from any future results,
performance or achievements expressed or implied by such
statements. The known risks, uncertainties and other factors
affecting these forward-looking statements are described from time
to time in Transgenomic's filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly,
the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not
undertake any duty to update this information, including any
forward-looking statements, unless required by law.
Media Contact:BLL Partners LLCBarbara Lindheim,
212-584-2276blindheim@bllbiopartners.comorInvestor
Contact:Argot PartnersSusan Kim,
212-600-1902susan@argotpartners.comorCompany
Contact:Transgenomic, Inc.Mark Colonnese, 203-907-2242Executive
Vice President and Chief Financial
Officerinvestorrelations@transgenomic.com
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024